Accelerates FLUENT’s entry into one of the largest and fastest growing cannabis markets in the world Enables FLUENT banner to expand its retail door count to 42, add on its first wholesale division as well as continue to expand its house of brands  One of the largest U.S. cannabis transactions of 2024, further bolstering FLUENT’s balance sheet with approximately US $33 million1,2 in cash just weeks after securing industry attractive refinancing that positions the Company to consider additional M&A and growth opportunities Acquires RIV Capital’s assets and cash balance in a debt-free, all stock transaction: The Hawthorne Collective completes exchange of its existing Convertible Notes in RIV Capital for a new class of non-voting Exchangeable Shares of Cansortium, eliminating US$160 million3 of debt Conference Call to be Held Today,...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Intelligent Ultrasound Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position...

Suite of software tools will empower ag lenders to streamline operations, find new customers faster, and build stronger relationships JOHNSTON, Iowa, Dec. 19, 2024 (GLOBE NEWSWIRE) — Growers Edge, a financial technology firm that provides modern financial products and data-driven tools for agricultural retailers, manufacturers, and lenders, today announced the acquisition of AQUAOSO Technologies, which offers its services under the Agcor brand and provides mapping, data, and analytics software for agricultural lenders. Many agricultural lenders undervalue weather, water, and climate risks in their financing decisions. Traditional land valuation methods don’t consider the impact of the worsening effects of climate change, which can include unpredictable fluctuations in temperature and precipitation that increase the frequency and...

El Septimo Enters the $350 Billion Global Luxury Market to Compete with Louis Vuitton, Hermes, Kering and RichemontBuilding on its revolutionary impact in cigars, accessories, fine wines, spirits, luxury hotels, golf courses, and resorts, as well as the establishment of MPA Creation—a cutting-edge luxury design center—El Septimo is now expanding into fashion and leather goods, perfumes, cosmetics, and fine jewelry.El Septimo Fashion Innovation: Unisex Cigar Smoking Suit Jackets in Various Colors – Available For Sale Online“We believe the luxury fashion industry has been facing many challenges, with one of the biggest being the lack of innovation and exclusivity,” says Zaya Younan. “Since the 1950s, there has been no significant improvement in the creation of new fashion. Back then, the major icons were...

WEST PALM BEACH, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) — HotelPlanner, a leading global provider of online group hotel bookings and individual room reservations, proudly announces its acquisition of PetsWelcome.com, a pioneering platform dedicated to helping travelers find pet-friendly accommodations. Founded in 1997 by Chris Kingsley and Fred Grayson, PetsWelcome.com has been a trusted resource for pet-loving travelers for over two decades. Driven by his passion as proud dog and cat owner, Chris Kingsley envisioned a platform that seamlessly connects travelers with hotels, bed-and-breakfasts, and inns that welcome not just people but their cherished pets. This acquisition marks a significant milestone in HotelPlanner’s mission to enhance the travel experience by providing greater inclusivity and convenience for all travelers,...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Equipmake Holdings plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position held/dealing...

Franklin Energy has acquired AESC and EVA Green Power, solidifying their spot as a market leader in the clean energy industry. By combining AESC’s engineering and consulting and EVA Green Power’s energy systems design and build expertise with Franklin Energy’s implementation, product manufacturing, and distribution capabilities, this acquisition creates an industry-leading provider of comprehensive energy solutions. PORT WASHINGTON, Wis, Dec. 19, 2024 (GLOBE NEWSWIRE) — Franklin Energy, a leader in comprehensive clean energy solutions for utilities, governments, and businesses, announced today the successful acquisitions of AESC, a national innovator in demand side management engineering and consulting specializing in energy efficiency and renewable energy, as well as EVA Green Power, a leading engineering, procurement, design...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ECKOH PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Strengthened Pipeline Targets Multiple Fibrotic Diseases MELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces the acquisition of OccuRx, a Melbourne-based biotechnology company with highly complementary assets, resources and expertise, and a shared focus on targeting GPR68, a master switch of fibrosis. The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Professor Darren Kelly, consolidating a pipeline that now includes two Phase 2 and one Phase 1 clinical candidates. Building on Professor Kelly’s pioneering research into inhibitors of GPR68 and benefiting from years of further development within biotechnology and major pharma...